Do you want to read an article? Please log in or register.
LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease
Breast Cancer
ESMO 2025
Related content
ESMO 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer
SABCS 2025
Breast Cancer
DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
COMMENTED
Breast Cancer
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 3
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
N Engl J Med
Loibl S, Park YH, Shao Z, Huang CS, Barrios C, Abraham J, Prat A, Niikura N, Im SA, Li W, Li H, Wang Y, Yao H, Kim SB, Geng CZ, Rodriguez Pantigoso W, Ramírez Godinez FJ, Song C, Ching Chang Y, Antoniazzi A, Chen SC, Li Z, Nowecki Z, Lim J, Mathias E, Sato Y, Lu W, Abdel-Monem H, Untch M, Geyer CE Jr, DESTINY-Breast05 Trial Investigators
doi: 10.1056/NEJMoa2514661
ESMO 2025
Breast Cancer
DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer
ESMO 2025
Breast Cancer
monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer
ESMO 2025
Breast Cancer
monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer
Breast Cancer
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
Ann Oncol
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF, DESTINY-Breast11 Trial Investigators
doi: 10.1016/j.annonc.2025.10.019
Breast Cancer
Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond
healthbook TIMES Onco Hema
Vetter M, Kurzeder C
doi: 10.36000/HBT.OH.2025.24.183